quinolinic acid has been researched along with Huntington Disease in 208 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "), a potent free radical scavenger against the unilateral stereotaxic induction of quinolinic acid (QA) (300 nm/4 μl saline)-induced Huntington disease (HD)-like symptoms in behavioral, biochemical, and histological features in male Wistar rats striatum." | 7.88 | Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone-a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats. ( Purushothaman, B; Ramachandran, S; Sumathi, T; Vedagiri, A, 2018) |
| "Indoleamine 2,3 dioxygenase (Ido1), the first and rate-limiting enzyme of the kynurenine pathway (KP), is a striatally enriched gene with increased expression levels in the YAC128 mouse model of Huntington disease (HD)." | 7.79 | Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. ( Adomat, H; Budac, DP; Leavitt, BR; Lu, G; Mazarei, G; Möller, T; Tomlinson Guns, ES, 2013) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 7.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| " Striatal injection of quinolinic acid (QUIN) resulted in marked inflammation characterized by microgliosis, astrogliosis and enhanced expressions of pro-inflammatory enzymes inducible nitric oxide synthase and cyclooxygenase-2." | 7.73 | Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. ( Choi, HB; McLarnon, JG; Ryu, JK, 2006) |
| "The concentration of the endogenous excitotoxin quinolinic acid was determined in the cerebrospinal fluid of drug-free patients suffering from Huntington's disease or schizophrenia (control group)." | 7.67 | Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. ( Kurlan, R; Schwarcz, R; Shoulson, I; Tamminga, CA, 1988) |
| "Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors." | 6.42 | Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003) |
| "Huntington Disease (HD), a predominant Neurodegenerative Disorder which might be induced by endogenous neurotoxin called Quinolinic Acid (QA), an N-methyl-D aspartate receptor (NMDAR) agonist, the bilaterally intrastriatal administration (200 nm/2 μL of saline) offers rise to the toxic events like neuronal death, neuroinflammation by inflicting excitotoxicity and oxidative stress in the striatum of male Wistar rats by exhibiting the behavioural changes which was accessed by rotarod, open field analysis." | 4.12 | 5,6,7 trihydroxy flavone armoured neurodegeneration caused by Quinolinic acid induced huntington's like disease in rat striatum - reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathol ( Purushothaman, B; Sumathi, T, 2022) |
| "We created an excitotoxic striatal lesion model of Huntington disease (HD) in sheep, using the N-methyl-d-aspartate receptor agonist, quinolinic acid (QA)." | 3.96 | Longitudinal Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging in Sheep (Ovis aries) With Quinolinic Acid Lesions of the Striatum: Time-Dependent Recovery of N-Acetylaspartate and Fractional Anisotropy. ( Finnie, JW; Hemsley, KM; Kuchel, TR; Morton, AJ; Neumann, D; O'Connell, AB; Perumal, SR; Sherwood, V, 2020) |
| "), a potent free radical scavenger against the unilateral stereotaxic induction of quinolinic acid (QA) (300 nm/4 μl saline)-induced Huntington disease (HD)-like symptoms in behavioral, biochemical, and histological features in male Wistar rats striatum." | 3.88 | Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone-a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats. ( Purushothaman, B; Ramachandran, S; Sumathi, T; Vedagiri, A, 2018) |
| "Indoleamine 2,3 dioxygenase (Ido1), the first and rate-limiting enzyme of the kynurenine pathway (KP), is a striatally enriched gene with increased expression levels in the YAC128 mouse model of Huntington disease (HD)." | 3.79 | Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. ( Adomat, H; Budac, DP; Leavitt, BR; Lu, G; Mazarei, G; Möller, T; Tomlinson Guns, ES, 2013) |
| " Striatal injection of quinolinic acid (QUIN) resulted in marked inflammation characterized by microgliosis, astrogliosis and enhanced expressions of pro-inflammatory enzymes inducible nitric oxide synthase and cyclooxygenase-2." | 3.73 | Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. ( Choi, HB; McLarnon, JG; Ryu, JK, 2006) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 3.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "Intrastriatal injection of quinolinic acid (QA) provides an animal model of Huntington disease." | 3.71 | Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy. ( Gruetter, R; Keene, CD; Low, WC; Pfeuffer, J; Tkác, I, 2001) |
| "Intrastriatal injections of quinolinic acid induce a pattern of neuronal degeneration similar to that seen in Huntington disease." | 3.69 | Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. ( Bartus, RT; Bayer, R; Charles, V; Friden, PM; Kordower, JH; Putney, S; Walus, LR, 1994) |
| " With the intent of producing a more reliable behavioral model of Huntington disease, anatomically-defined lesions of limited size were produced by magnetic resonance imaging-guided stereotaxic injection of quinolinic acid in specific regions within the caudate and putamen of rhesus monkeys." | 3.69 | Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. ( Brownell, AL; Burns, LH; Deacon, TW; Isacson, O; Jenkins, BG; Pakzaban, P; Tatter, SB, 1995) |
| "The concentration of the endogenous excitotoxin quinolinic acid was determined in the cerebrospinal fluid of drug-free patients suffering from Huntington's disease or schizophrenia (control group)." | 3.67 | Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. ( Kurlan, R; Schwarcz, R; Shoulson, I; Tamminga, CA, 1988) |
| "An excess of the tryptophan metabolite quinolinic acid in the brain has been hypothetically related to the pathogenesis of Huntington disease." | 3.67 | 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. ( Bird, ED; Okuno, E; Schwarcz, R; Whetsell, WO; White, RJ, 1988) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "The neurodegenerative disease Huntington's disease (HD) is caused by an expanded polyglutamine (polyQ) tract in the protein huntingtin (htt)." | 2.46 | Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. ( Guidetti, P; Muchowski, PJ; Sathyasaikumar, KV; Schwarcz, R, 2010) |
| "Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors." | 2.42 | Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003) |
| "Huntington Disease is autosomal, fatal and progressive neurodegenerative disorder for which clinically available drugs offer only symptomatic relief." | 1.46 | Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation. ( Deshmukh, R; Gill, JS; Jamwal, S; Kumar, P, 2017) |
| "Quinolinic acid (QA) is an excitotoxin that induces Huntington's-like symptoms in animals and humans." | 1.43 | Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats. ( Kumar, P; Singh, S, 2016) |
| "Huntington disease is hyperkinetic movement disorder characterized by selective and immense degradation of GABAergic medium spiny neurons in striatum." | 1.42 | Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism. ( Jamwal, S; Kaur, N; Kumar, P; Singh, S, 2015) |
| "Treatment with rosiglitazone (5, 10 mg/kg) and VPA (100, 200 mg/kg) for 21 days significantly attenuated these behavioral, biochemical, and cellular alterations as compared to control (QA 200 nmol) group." | 1.40 | Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways. ( Chaudhary, T; Kumar, A; Mishra, J, 2014) |
| "Melatonin was partially effective against the inhibition of striatal catalase activity and a decrease of non-protein thiol levels induced by quinolinic acid." | 1.39 | Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin. ( Antunes Wilhelm, E; Folharini Bortolatto, C; Ricardo Jesse, C; Wayne Nogueira, C, 2013) |
| " Our data suggest that the two studied toxic models (QA and 3-NP) or the combined model (QA plus 3-NP) can generate complex patterns of damage, which involve metabolic compromise, ROS formation, and oxidative stress." | 1.38 | Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. ( Colle, D; Farina, M; Hartwig, JM; Soares, FA, 2012) |
| "Because Huntington's disease mouse models develop resistance to excitotoxicity, we analyzed whether decreased STEP activity was involved in this process." | 1.37 | Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. ( Alberch, J; Giralt, A; Lombroso, PJ; Lucas, JJ; Ortega, Z; Pérez-Navarro, E; Rué, L; Saavedra, A; Xifró, X; Xu, J, 2011) |
| "Quinolinic acid (300 nmol) was administered intrastriatally into the striatum to induce Huntington's disease-like alteration." | 1.37 | Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats. ( Kalonia, H; Kumar, A, 2011) |
| "Huntington disease is a neurodegenerative disease with complex pathophysiology." | 1.37 | Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. ( Kalonia, H; Kumar, A; Kumar, P, 2011) |
| " Moreover, the administration of MK-801 to rats as a pretreatment resulted in a complete prevention of the QUIN-induced NAD(P)H activation, suggesting that this toxic event is completely dependent on N-methyl-D-aspartate receptor overactivation." | 1.36 | NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/prooxidant model of Huntington's disease in rats: protective role of apocynin. ( Galván-Arzate, S; Maldonado, PD; Molina-Jijón, E; Pedraza-Chaverrí, J; Santamaría, A; Villeda-Hernández, J, 2010) |
| " However, the administration system and the control over the dosage are still important problems to be solved." | 1.36 | BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. ( Alberch, J; Blanco, J; Canals, JM; Caneda-Ferrón, B; Friedman, HC; Giralt, A; Moreno, E; Peterson, A; Rubio, N; Urbán, N, 2010) |
| "Huntington's disease is an inherited neurodegenerative disorder, characterized by loss of spiny neurons in the striatum and cortex, which usually happens in the third or fourth decades of life." | 1.35 | Microanatomical evidences for potential of mesenchymal stem cells in amelioration of striatal degeneration. ( Ali, M; Amin, EM; Maryam, MM; Morteza, BR; Reza, BA; Zeinab, N, 2008) |
| " The injection coordinates and the dosage of quinolinic acid were identical." | 1.35 | Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease. ( Büchele, F; Döbrössy, M; Jiang, W; Nikkhah, G; Papazoglou, A, 2009) |
| "However, in Huntington's disease there is a very early downregulation of CB(1) receptors in striatal neurons that, together with the undesirable psychoactive effects triggered by CB(1) receptor activation, foster the search for alternative pharmacological treatments." | 1.35 | Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. ( Aguado, T; Azcoitia, I; Benito, C; Carrasco, C; Fernández-Ruiz, J; Galve-Roperh, I; Guzmán, M; Julien, B; Palazuelos, J; Pazos, MR; Resel, E; Romero, J; Sagredo, O, 2009) |
| "Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington's disease (HD), by stimulating NMDA receptors." | 1.35 | Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. ( Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2009) |
| "In patients with Huntington's disease (HD), the proteolytic activity of the ubiquitin proteasome system (UPS) is reduced in the brain and other tissues." | 1.34 | Proteasome activator enhances survival of Huntington's disease neuronal model cells. ( Cattaneo, E; Isacson, O; Kim, W; Seo, H; Sonntag, KC, 2007) |
| "However, its potential in Huntington's disease (HD) models characterized by calpain-dependent degeneration and inflammation has not been investigated." | 1.33 | Minocycline in phenotypic models of Huntington's disease. ( Bantubungi, K; Blum, D; Brotchi, J; Brouillet, E; Chtarto, A; Déglon, N; Galas, MC; Greco, A; Jacquard, C; Levivier, M; Minghetti, L; Pintor, A; Popoli, P; Schiffmann, SN; Tai, K; Tenenbaum, L, 2005) |
| "Huntington's disease is an inherited neurodegenerative condition characterized by movement disorders, and mood and cognitive disturbance." | 1.33 | Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease. ( Barker, RA; Morton, AJ; Phillips, W, 2006) |
| "Quinolinic acid (QA) has been shown to evoke neurotoxic events via NMDA receptor (NMDAR) overactivation and oxidative stress." | 1.33 | Quinolinic acid modulates the activity of src family kinases in rat striatum: in vivo and in vitro studies. ( Di Stasi, AM; Domenici, MR; Mallozzi, C; Metere, A; Minetti, M; Pèzzola, A; Popoli, P, 2006) |
| "Symptoms in the early stages of Huntington's disease (HD) are assumed to reflect basal ganglia circuit dysfunction secondary to degeneration of striatal projections to the external segment of the globus pallidus (GPe)." | 1.32 | Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: a potential novel treatment in a rat model of Huntington's disease. ( Ayalon, L; Joel, D; Tarrasch, R; Weiner, I, 2003) |
| " A lower pyruvate concentration of 250 mg/kg was not protective; however, quadruple applications at this dosage was effective in reducing lesion volumes." | 1.32 | Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease. ( Kim, SU; McLarnon, JG; Ryu, JK, 2003) |
| " These results establish the proof of principle of neurotrophic factor dosing for neurodegenerative diseases and demonstrate the feasibility of lentiviral-mediated tetracycline-regulated gene transfer in the brain." | 1.31 | Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. ( Aebischer, P; Déglon, N; Pereira de Almeida, L; Régulier, E; Sommer, B, 2002) |
| "Quinolinic acid (QA) is an N-methyl-d-aspartate agonist that has been shown to produce neurotoxic effects that mimic certain neurodegenerative diseases when administered to laboratory animals." | 1.31 | Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease. ( Dunbar, GL; Haik, KL; Sabel, BA; Schroeder, U; Shear, DA, 2000) |
| "Huntington's disease is an autosomal dominant hereditary neurodegenerative disorder characterized by severe striatal cell loss." | 1.31 | Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. ( Brundin, P; Castilho, RF; DiFiglia, M; Hansson, O; Petersén, A; Przedborski, S; Puschban, Z; Rice, M; Romero, N; Sapp, E; Sulzer, D, 2001) |
| "Striatal neurons in symptomatic Huntington's disease (HD) transgenic mice are resistant to a variety of toxic insults, including quinolinic acid (QA), kainic acid and 3-nitropropionic acid." | 1.31 | Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice. ( Costain, WJ; Crocker, SF; Denovan-Wright, EM; Hamilton, LC; MacGibbon, GA; Murphy, KM; Robertson, HA, 2002) |
| "Huntington's disease is a progressive neurodegenerative disease characterized by movement disorder, cognitive deterioration, and selective striatal degeneration." | 1.31 | Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. ( Emborg, ME; Kordower, JH; Palfi, S; Roitberg, BZ; Sramek, JG, 2002) |
| "A transgenic mouse model of Huntington's disease (R6/1 and R6/2 lines) expressing exon 1 of the HD gene with 115-150 CAG repeats resisted striatal damage following injection of quinolinic acid and other neurotoxins." | 1.31 | Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. ( Aronin, N; Brundin, P; Chase, K; DiFiglia, M; Petersén, A; Puschban, Z, 2002) |
| "Huntington's disease is a progressive, inherited neurodegenerative disorder characterized by the loss of subsets of neurons primarily in the striatum." | 1.31 | Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. ( Chuang, DM; Qian, Y; Qin, ZH; Senatorov, VV; Wang, Y; Wei, H; Wei, W, 2001) |
| "Using this animal model of Huntington's disease, we investigated the ability of the insulin-like growth factor-I (IGF-I) amino-terminal tripeptide glycine-proline-glutamate (GPE) to protect striatal neurons from degeneration." | 1.30 | The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. ( Alexi, T; Clark, RG; Faull, RL; Gluckman, PD; Hughes, PE; van Roon-Mom, WM; Williams, CE, 1999) |
| "Huntington's disease is a genetic disorder that results from degeneration of striatal neurons, particularly those containing GABA (gamma-aminobutyric acid)." | 1.30 | Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. ( Baetge, EE; Chen, EY; Chu, Y; Emerich, DF; Hantraye, PM; Kordower, JH; McDermott, P; Peschanski, M; Winn, SR, 1997) |
| "Using this animal model of human Huntington's disease we investigated the effect of daily intrastriatal infusion of the nerve cell survival molecule ActivinA (single bolus dose of 0." | 1.30 | Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. ( Alexi, T; Clark, RG; Gluckman, PD; Hughes, PE; Williams, CE, 1999) |
| "In the Huntington's disease cases, calbindin labeling was markedly increased throughout the second and third order dendrites and in spines, and this change was more prevalent in advanced cases (grades 3-4)." | 1.29 | Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. ( Aizawa, H; Bird, ED; DiFiglia, M; Ge, P; Huang, Q; Sapp, E; Vonsattel, JP; Zhou, D, 1995) |
| "Huntington disease is a dominantly inherited, untreatable neurological disorder featuring a progressive loss of striatal output neurons that results in dyskinesia, cognitive decline, and, ultimately, death." | 1.29 | Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. ( Anderson, KD; Corcoran, TL; Lindsay, RM; Panayotatos, N; Wiegand, SJ, 1996) |
| " Morphological criteria were used to determine the toxic effects of glutamate in 6-, 12-, and 18-day-old cultures which were examined before and after 1-3 h of exposure to glutamate." | 1.28 | Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures. ( Beal, MF; DiFiglia, M; Freese, A; Koroshetz, WJ; Martin, JB, 1990) |
| "Quinolinic acid (QA) content was measured in postmortem frontal and temporal cortex, putamen and cerebellum obtained from patients with senile dementia of Alzheimer type (SDAT), Huntington's disease (HD) and controls, using a gas chromatography/mass spectrometry method." | 1.28 | Brain quinolinic acid in Alzheimer's dementia. ( Beckmann, H; Halket, J; Jellinger, K; Przyborowska, A; Riederer, P; Sandler, M; Sofic, E, 1989) |
| "Adenosine A2 receptors were labeled and visualized by autoradiography in tissue sections of the human brain using the A2-selective agonist ligand [3H](2-p-(2-carboxyethyl)phenylamino)-5'-N-carboxamidoadenosine (CGS 21680)." | 1.28 | Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. ( Martinez-Mir, MI; Palacios, JM; Probst, A, 1991) |
| "Using the excitotoxic animal model of Huntington's disease, two experimental treatments were evaluated." | 1.28 | Neural grafts and pharmacological intervention in a model of Huntington's disease. ( Ford, LM; Giordano, M; Sanberg, PR; Shipley, MT, 1990) |
| "Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD)." | 1.27 | Systemic approaches to modifying quinolinic acid striatal lesions in rats. ( Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988) |
| "We conclude that Huntington's disease is not associated with a generalised disturbance of quinolinic acid metabolism, however, a local hyperproduction of quinolinic acid cannot be excluded from our results." | 1.27 | Normal excretion of quinolinic acid in Huntington's disease. ( Brown, RR; Garnett, ES; Heyes, MP, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (6.25) | 18.7374 |
| 1990's | 57 (27.40) | 18.2507 |
| 2000's | 86 (41.35) | 29.6817 |
| 2010's | 42 (20.19) | 24.3611 |
| 2020's | 10 (4.81) | 2.80 |
| Authors | Studies |
|---|---|
| Martínez-Gopar, PE | 2 |
| Pérez-Rodríguez, MJ | 1 |
| Rodríguez-Manzo, G | 1 |
| Garduño-Gutierrez, R | 1 |
| Tristán-López, L | 2 |
| Angeles-López, QD | 1 |
| González-Espinosa, C | 1 |
| Pérez-Severiano, F | 4 |
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Bains, M | 1 |
| Kaur, J | 1 |
| Akhtar, A | 2 |
| Kuhad, A | 2 |
| Sah, SP | 2 |
| Yedke, NG | 1 |
| Arthur, R | 1 |
| Kumar, P | 8 |
| Yoon, Y | 1 |
| Kim, HS | 1 |
| Jeon, I | 1 |
| Noh, JE | 1 |
| Park, HJ | 1 |
| Lee, S | 1 |
| Park, IH | 1 |
| Stevanato, L | 1 |
| Hicks, C | 1 |
| Corteling, R | 1 |
| Barker, RA | 4 |
| Sinden, JD | 1 |
| Song, J | 2 |
| Thomsen, MB | 1 |
| Jacobsen, J | 1 |
| Lillethorup, TP | 1 |
| Schacht, AC | 1 |
| Simonsen, M | 1 |
| Romero-Ramos, M | 1 |
| Brooks, DJ | 1 |
| Landau, AM | 1 |
| O'Connell, AB | 1 |
| Kuchel, TR | 1 |
| Perumal, SR | 1 |
| Sherwood, V | 1 |
| Neumann, D | 1 |
| Finnie, JW | 1 |
| Hemsley, KM | 1 |
| Morton, AJ | 2 |
| Stepanova, P | 1 |
| Srinivasan, V | 1 |
| Lindholm, D | 1 |
| Voutilainen, MH | 1 |
| Saroj, P | 1 |
| Bansal, Y | 1 |
| Singh, R | 1 |
| Sodhi, RK | 1 |
| Bishnoi, M | 1 |
| Purushothaman, B | 2 |
| Sumathi, T | 2 |
| Harrison, DJ | 1 |
| Roberton, VH | 1 |
| Vinh, NN | 1 |
| Brooks, SP | 1 |
| Dunnett, SB | 9 |
| Rosser, AE | 2 |
| Lelos, MJ | 2 |
| Vedagiri, A | 1 |
| Ramachandran, S | 1 |
| Lavisse, S | 1 |
| Williams, S | 1 |
| Lecourtois, S | 1 |
| van Camp, N | 1 |
| Guillermier, M | 1 |
| Gipchtein, P | 1 |
| Jan, C | 1 |
| Goutal, S | 1 |
| Eymin, L | 1 |
| Valette, J | 1 |
| Delzescaux, T | 1 |
| Perrier, AL | 2 |
| Hantraye, P | 2 |
| Aron Badin, R | 1 |
| Mazarei, G | 2 |
| Budac, DP | 2 |
| Lu, G | 4 |
| Adomat, H | 1 |
| Tomlinson Guns, ES | 1 |
| Möller, T | 2 |
| Leavitt, BR | 5 |
| Strong, MK | 1 |
| Southwell, AL | 1 |
| Yonan, JM | 1 |
| Hayden, MR | 4 |
| Macgregor, GR | 1 |
| Thompson, LM | 2 |
| Steward, O | 2 |
| Schackel, S | 1 |
| Pauly, MC | 1 |
| Piroth, T | 1 |
| Nikkhah, G | 2 |
| Döbrössy, MD | 3 |
| Lee, H | 1 |
| Kumar, A | 9 |
| Chaudhary, T | 2 |
| Mishra, J | 4 |
| Mu, S | 1 |
| Wang, J | 1 |
| Zhou, G | 1 |
| Peng, W | 1 |
| He, Z | 1 |
| Zhao, Z | 1 |
| Mo, C | 1 |
| Qu, J | 1 |
| Zhang, J | 1 |
| Martínez-Lazcano, JC | 2 |
| Montes, S | 2 |
| Sánchez-Mendoza, MA | 1 |
| Rodríguez-Páez, L | 1 |
| Pérez-Neri, I | 2 |
| Boll, MC | 1 |
| Campos-Arroyo, HD | 1 |
| Ríos, C | 2 |
| Giorgetto, C | 1 |
| Silva, EC | 1 |
| Kitabatake, TT | 1 |
| Bertolino, G | 1 |
| de Araujo, JE | 1 |
| Jamwal, S | 2 |
| Singh, S | 2 |
| Kaur, N | 1 |
| Morales-Martínez, A | 1 |
| Sánchez-Mendoza, A | 1 |
| Pineda-Farías, JB | 1 |
| El-Hafidi, M | 1 |
| Zamorano-Carrillo, A | 1 |
| Castro, N | 1 |
| Beaumont, V | 1 |
| Mrzljak, L | 1 |
| Dijkman, U | 1 |
| Freije, R | 1 |
| Heins, M | 1 |
| Rassoulpour, A | 1 |
| Tombaugh, G | 1 |
| Gelman, S | 1 |
| Bradaia, A | 1 |
| Steidl, E | 1 |
| Gleyzes, M | 1 |
| Heikkinen, T | 1 |
| Lehtimäki, K | 1 |
| Puoliväli, J | 1 |
| Kontkanen, O | 1 |
| Javier, RM | 1 |
| Neagoe, I | 1 |
| Deisemann, H | 1 |
| Winkler, D | 1 |
| Ebneth, A | 1 |
| Khetarpal, V | 1 |
| Toledo-Sherman, L | 1 |
| Dominguez, C | 1 |
| Park, LC | 1 |
| Munoz-Sanjuan, I | 1 |
| Tartaglione, AM | 1 |
| Armida, M | 1 |
| Potenza, RL | 1 |
| Pezzola, A | 9 |
| Popoli, P | 10 |
| Calamandrei, G | 3 |
| Gill, JS | 1 |
| Deshmukh, R | 1 |
| Karl, JM | 1 |
| Sacrey, LA | 1 |
| McDonald, RJ | 1 |
| Whishaw, IQ | 1 |
| Amin, EM | 1 |
| Reza, BA | 1 |
| Morteza, BR | 1 |
| Maryam, MM | 1 |
| Ali, M | 1 |
| Zeinab, N | 1 |
| Aubry, L | 1 |
| Bugi, A | 1 |
| Lefort, N | 1 |
| Rousseau, F | 1 |
| Peschanski, M | 2 |
| Patassini, S | 4 |
| Giampà, C | 6 |
| Martorana, A | 4 |
| Bernardi, G | 6 |
| Fusco, FR | 7 |
| Pérez-De La Cruz, V | 2 |
| Elinos-Calderón, D | 1 |
| Robledo-Arratia, Y | 1 |
| Medina-Campos, ON | 1 |
| Pedraza-Chaverrí, J | 3 |
| Ali, SF | 1 |
| Santamaría, A | 4 |
| Graham, RK | 3 |
| Pouladi, MA | 1 |
| Joshi, P | 1 |
| Deng, Y | 2 |
| Wu, NP | 1 |
| Figueroa, BE | 1 |
| Metzler, M | 1 |
| André, VM | 1 |
| Slow, EJ | 3 |
| Raymond, L | 1 |
| Friedlander, R | 1 |
| Levine, MS | 1 |
| Borreca, A | 1 |
| Laurenti, D | 1 |
| Marullo, F | 1 |
| Menniti, FS | 1 |
| Schwarcz, R | 8 |
| Guidetti, P | 5 |
| Sathyasaikumar, KV | 1 |
| Muchowski, PJ | 1 |
| Jiang, W | 1 |
| Büchele, F | 1 |
| Papazoglou, A | 1 |
| Döbrössy, M | 1 |
| Emerich, DF | 5 |
| Mooney, DJ | 1 |
| Storrie, H | 1 |
| Babu, RS | 1 |
| Kordower, JH | 6 |
| Velloso, NA | 1 |
| Dalmolin, GD | 1 |
| Gomes, GM | 1 |
| Rubin, MA | 1 |
| Canas, PM | 1 |
| Cunha, RA | 1 |
| Mello, CF | 1 |
| Xifró, X | 2 |
| Giralt, A | 3 |
| Saavedra, A | 2 |
| García-Martínez, JM | 1 |
| Díaz-Hernández, M | 1 |
| Lucas, JJ | 2 |
| Alberch, J | 8 |
| Pérez-Navarro, E | 7 |
| Maldonado, PD | 1 |
| Molina-Jijón, E | 1 |
| Villeda-Hernández, J | 1 |
| Galván-Arzate, S | 1 |
| Palazuelos, J | 1 |
| Aguado, T | 1 |
| Pazos, MR | 1 |
| Julien, B | 1 |
| Carrasco, C | 1 |
| Resel, E | 1 |
| Sagredo, O | 1 |
| Benito, C | 1 |
| Romero, J | 1 |
| Azcoitia, I | 1 |
| Fernández-Ruiz, J | 1 |
| Guzmán, M | 1 |
| Galve-Roperh, I | 1 |
| Kalonia, H | 5 |
| Nehru, B | 1 |
| Lee, ST | 4 |
| Chu, K | 4 |
| Jung, KH | 1 |
| Im, WS | 1 |
| Park, JE | 4 |
| Lim, HC | 1 |
| Won, CH | 1 |
| Shin, SH | 1 |
| Lee, SK | 1 |
| Kim, M | 4 |
| Roh, JK | 2 |
| Sanagi, T | 1 |
| Yabe, T | 1 |
| Yamada, H | 1 |
| Vazey, EM | 2 |
| Dottori, M | 1 |
| Jamshidi, P | 1 |
| Tomas, D | 1 |
| Pera, MF | 1 |
| Horne, M | 1 |
| Connor, B | 5 |
| Friedman, HC | 1 |
| Caneda-Ferrón, B | 1 |
| Urbán, N | 1 |
| Moreno, E | 1 |
| Rubio, N | 1 |
| Blanco, J | 1 |
| Peterson, A | 1 |
| Canals, JM | 4 |
| Casteels, C | 1 |
| Martinez, E | 1 |
| Bormans, G | 1 |
| Camon, L | 1 |
| de Vera, N | 1 |
| Baekelandt, V | 1 |
| Planas, AM | 1 |
| Van Laere, K | 1 |
| Rekik, L | 1 |
| Daguin-Nerrière, V | 1 |
| Petit, JY | 1 |
| Brachet, P | 2 |
| Rué, L | 1 |
| Xu, J | 1 |
| Ortega, Z | 1 |
| Lombroso, PJ | 1 |
| Lin, YT | 1 |
| Chern, Y | 1 |
| Shen, CK | 1 |
| Wen, HL | 1 |
| Chang, YC | 1 |
| Li, H | 1 |
| Cheng, TH | 1 |
| Hsieh-Li, HM | 1 |
| Colle, D | 1 |
| Hartwig, JM | 1 |
| Soares, FA | 1 |
| Farina, M | 1 |
| Sadan, O | 1 |
| Shemesh, N | 1 |
| Barzilay, R | 1 |
| Dadon-Nahum, M | 1 |
| Blumenfeld-Katzir, T | 1 |
| Assaf, Y | 1 |
| Yeshurun, M | 1 |
| Djaldetti, R | 1 |
| Cohen, Y | 1 |
| Melamed, E | 1 |
| Offen, D | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Klein, A | 1 |
| Lane, EL | 1 |
| McLeod, MC | 1 |
| Kobayashi, NR | 1 |
| Sen, A | 1 |
| Baghbaderani, BA | 1 |
| Sadi, D | 1 |
| Ulalia, R | 1 |
| Behie, LA | 1 |
| Mendez, I | 1 |
| Delli Carri, A | 1 |
| Onorati, M | 1 |
| Castiglioni, V | 1 |
| Faedo, A | 1 |
| Menon, R | 1 |
| Camnasio, S | 1 |
| Vuono, R | 1 |
| Spaiardi, P | 1 |
| Talpo, F | 1 |
| Toselli, M | 1 |
| Martino, G | 1 |
| Biella, G | 1 |
| Cattaneo, E | 4 |
| Antunes Wilhelm, E | 1 |
| Ricardo Jesse, C | 1 |
| Folharini Bortolatto, C | 1 |
| Wayne Nogueira, C | 1 |
| Régulier, E | 1 |
| Pereira de Almeida, L | 1 |
| Sommer, B | 1 |
| Aebischer, P | 3 |
| Déglon, N | 4 |
| Ishiwata, K | 1 |
| Ogi, N | 1 |
| Hayakawa, N | 1 |
| Oda, K | 1 |
| Nagaoka, T | 1 |
| Toyama, H | 1 |
| Suzuki, F | 1 |
| Endo, K | 1 |
| Tanaka, A | 1 |
| Senda, M | 1 |
| Gianfriddo, M | 1 |
| Corsi, C | 1 |
| Melani, A | 1 |
| Reggio, R | 5 |
| Pedata, F | 1 |
| Stone, TW | 2 |
| Mackay, GM | 1 |
| Forrest, CM | 1 |
| Clark, CJ | 1 |
| Darlington, LG | 1 |
| Zuccato, C | 2 |
| Tartari, M | 1 |
| De March, Z | 2 |
| Ryu, JK | 4 |
| Kim, SU | 4 |
| McLarnon, JG | 4 |
| Joel, D | 3 |
| Ayalon, L | 3 |
| Tarrasch, R | 2 |
| Weiner, I | 3 |
| Senatorov, VV | 2 |
| Ren, M | 1 |
| Kanai, H | 1 |
| Wei, H | 2 |
| Chuang, DM | 3 |
| Doron, R | 1 |
| Hussain, N | 1 |
| Flumerfelt, BA | 1 |
| Rajakumar, N | 1 |
| Haas, SJ | 1 |
| Ahrens, A | 1 |
| Petrov, S | 1 |
| Schmitt, O | 1 |
| Wree, A | 1 |
| Kells, AP | 3 |
| Fong, DM | 1 |
| Dragunow, M | 2 |
| During, MJ | 1 |
| Young, D | 1 |
| Winn, SR | 2 |
| Scattoni, ML | 2 |
| Valanzano, A | 2 |
| McBride, JL | 2 |
| Behrstock, SP | 1 |
| Chen, EY | 2 |
| Jakel, RJ | 1 |
| Siegel, I | 1 |
| Svendsen, CN | 1 |
| Tattersfield, AS | 1 |
| Croon, RJ | 1 |
| Liu, YW | 1 |
| Faull, RL | 5 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| Borlongan, CV | 3 |
| Skinner, SJ | 2 |
| Geaney, M | 2 |
| Vasconcellos, AV | 1 |
| Elliott, RB | 1 |
| Luthi-Carter, RE | 1 |
| Augood, SJ | 1 |
| Bantubungi, K | 1 |
| Jacquard, C | 1 |
| Greco, A | 1 |
| Pintor, A | 2 |
| Chtarto, A | 1 |
| Tai, K | 1 |
| Galas, MC | 1 |
| Tenenbaum, L | 1 |
| Minghetti, L | 1 |
| Brouillet, E | 1 |
| Brotchi, J | 1 |
| Levivier, M | 3 |
| Schiffmann, SN | 1 |
| Blum, D | 1 |
| Scherfler, C | 1 |
| Scholz, SW | 1 |
| Donnemiller, E | 1 |
| Decristoforo, C | 1 |
| Oberladstätter, M | 1 |
| Stefanova, N | 1 |
| Diederen, E | 1 |
| Virgolini, I | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Rite, I | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Venero, JL | 2 |
| Lee, K | 2 |
| Kang, L | 2 |
| Choi, HB | 2 |
| Liang, ZQ | 1 |
| Wang, XX | 1 |
| Wang, Y | 2 |
| DiFiglia, M | 5 |
| Chase, TN | 2 |
| Qin, ZH | 2 |
| Sapko, MT | 1 |
| Yu, P | 1 |
| Tagle, DA | 1 |
| Pellicciari, R | 1 |
| Visnyei, K | 1 |
| Tatsukawa, KJ | 2 |
| Erickson, RI | 1 |
| Simonian, S | 1 |
| Oknaian, N | 1 |
| Carmichael, ST | 1 |
| Kornblum, HI | 2 |
| DeMarch, Z | 2 |
| D'Angelo, V | 1 |
| Morello, M | 1 |
| Sancesario, G | 1 |
| Winkler, C | 1 |
| Gil, JM | 1 |
| Araújo, IM | 1 |
| Riess, O | 1 |
| Skripuletz, T | 1 |
| von Hörsten, S | 1 |
| Petersén, A | 4 |
| Chen, K | 1 |
| Hughes, SM | 1 |
| Metere, A | 1 |
| Mallozzi, C | 1 |
| Minetti, M | 1 |
| Domenici, MR | 3 |
| Di Stasi, AM | 1 |
| Bates, GP | 1 |
| MacDonald, ME | 1 |
| Wheeler, VC | 1 |
| Woodman, B | 1 |
| Haigh, B | 1 |
| Bissada, N | 1 |
| Pearson, J | 1 |
| Shehadeh, J | 1 |
| Bertram, L | 1 |
| Murphy, Z | 1 |
| Warby, SC | 1 |
| Doty, CN | 1 |
| Roy, S | 1 |
| Wellington, CL | 1 |
| Raymond, LA | 1 |
| Nicholson, DW | 1 |
| Phillips, W | 1 |
| March, ZD | 1 |
| McLin, JP | 1 |
| Seo, H | 1 |
| Sonntag, KC | 1 |
| Kim, W | 1 |
| Isacson, O | 6 |
| Kang, W | 1 |
| Lee, SE | 1 |
| Hwang, T | 1 |
| Chung, H | 1 |
| Ramaswamy, S | 1 |
| Aguilera, P | 1 |
| Chánez-Cárdenas, ME | 1 |
| Floriano-Sánchez, E | 1 |
| Barrera, D | 1 |
| Sánchez-González, DJ | 1 |
| Jiménez, PD | 1 |
| Estrada Sánchez, AM | 1 |
| Mejía-Toiber, J | 1 |
| Massieu, L | 1 |
| Bari, M | 1 |
| Gasperi, V | 1 |
| De Ceballos, ML | 1 |
| Maccarrone, M | 1 |
| Henry, RA | 1 |
| Thanos, CG | 1 |
| Köhler, C | 1 |
| Nicholson, LF | 3 |
| Waldvogel, HJ | 3 |
| Carlock, L | 1 |
| Walker, PD | 1 |
| Shan, Y | 1 |
| Gutridge, K | 1 |
| Tatter, SB | 2 |
| Galpern, WR | 1 |
| Hoogeveen, AT | 1 |
| Portera-Cailliau, C | 1 |
| Hedreen, JC | 1 |
| Price, DL | 1 |
| Koliatsos, VE | 1 |
| Burns, LH | 1 |
| Pakzaban, P | 1 |
| Deacon, TW | 1 |
| Brownell, AL | 2 |
| Jenkins, BG | 1 |
| Huang, Q | 1 |
| Zhou, D | 1 |
| Sapp, E | 2 |
| Aizawa, H | 1 |
| Ge, P | 1 |
| Bird, ED | 3 |
| Vonsattel, JP | 1 |
| Randall, TS | 1 |
| Cahill, DW | 1 |
| Sanberg, PR | 4 |
| Sagratella, S | 1 |
| Diana, G | 1 |
| Caporali, MG | 2 |
| Bronzetti, E | 1 |
| Vega, J | 1 |
| Scotti de Carolis, A | 2 |
| Figueredo-Cardenas, G | 1 |
| Anderson, KD | 2 |
| Chen, Q | 1 |
| Veenman, CL | 1 |
| Reiner, A | 1 |
| Beck, KD | 1 |
| Hefti, F | 1 |
| Milstien, S | 1 |
| Sakai, N | 1 |
| Brew, BJ | 1 |
| Krieger, C | 1 |
| Vickers, JH | 1 |
| Saito, K | 1 |
| Heyes, MP | 3 |
| Charles, V | 1 |
| Bayer, R | 1 |
| Bartus, RT | 1 |
| Putney, S | 1 |
| Walus, LR | 1 |
| Friden, PM | 1 |
| Synek, BJ | 1 |
| Pascoe, M | 1 |
| Schwarz, M | 3 |
| Block, F | 3 |
| Töpper, R | 2 |
| Gehrmann, J | 1 |
| Noth, J | 2 |
| Kreutzberg, GW | 1 |
| Frim, DM | 1 |
| Short, MP | 2 |
| Rosenberg, WS | 1 |
| Simpson, J | 1 |
| Breakefield, XO | 2 |
| Ferrante, RJ | 3 |
| Kowall, NW | 3 |
| Cipolloni, PB | 1 |
| Storey, E | 1 |
| Beal, MF | 6 |
| Schapira, AH | 1 |
| Furtado, JC | 1 |
| Mazurek, MF | 2 |
| Panayotatos, N | 1 |
| Corcoran, TL | 1 |
| Lindsay, RM | 1 |
| Wiegand, SJ | 1 |
| Nakao, N | 2 |
| Grasbon-Frodl, EM | 1 |
| Widner, H | 1 |
| Brundin, P | 4 |
| Hantraye, PM | 1 |
| Chu, Y | 1 |
| McDermott, P | 1 |
| Baetge, EE | 1 |
| Araujo, DM | 2 |
| Hilt, DC | 1 |
| Reynolds, NC | 1 |
| Lin, W | 1 |
| Meyer Cameron, C | 1 |
| Roerig, DL | 1 |
| Przedborski, S | 2 |
| Veenman, L | 1 |
| Feldon, J | 1 |
| Harris, CA | 1 |
| Miranda, AF | 1 |
| Tanguay, JJ | 1 |
| Boegman, RJ | 1 |
| Beninger, RJ | 1 |
| Jhamandas, K | 2 |
| Watts, C | 2 |
| Brasted, PJ | 2 |
| Robbins, TW | 1 |
| Shear, DA | 2 |
| Dong, J | 1 |
| Gundy, CD | 1 |
| Haik-Creguer, KL | 1 |
| Dunbar, GL | 2 |
| Martel, J | 1 |
| Chopin, P | 1 |
| Colpaert, F | 1 |
| Marien, M | 1 |
| Marco, S | 4 |
| Checa, N | 2 |
| Michels, A | 2 |
| Arenas, E | 5 |
| Ogura, M | 1 |
| Nakai, K | 1 |
| Itakura, T | 1 |
| Hughes, PE | 2 |
| Alexi, T | 2 |
| Williams, CE | 2 |
| Clark, RG | 2 |
| Gluckman, PD | 2 |
| Hansson, O | 2 |
| Leist, M | 1 |
| Nicotera, P | 1 |
| Castilho, RF | 2 |
| Bordelon, YM | 1 |
| Chesselet, MF | 1 |
| van Roon-Mom, WM | 1 |
| Brickell, KL | 1 |
| Menei, P | 1 |
| Pean, JM | 1 |
| Nerrière-Daguin, V | 1 |
| Jollivet, C | 1 |
| Benoit, JP | 1 |
| Guzman, R | 1 |
| Lövblad, KO | 1 |
| Meyer, M | 1 |
| Spenger, C | 1 |
| Schroth, G | 1 |
| Widmer, HR | 1 |
| Haik, KL | 1 |
| Schroeder, U | 1 |
| Sabel, BA | 1 |
| Akerud, P | 2 |
| Tolosa, E | 3 |
| Gouhier, C | 1 |
| Chalon, S | 1 |
| Venier-Julienne, MC | 1 |
| Bodard, S | 1 |
| Benoit, J | 1 |
| Besnard, J | 1 |
| Guilloteau, D | 1 |
| Donaldson, D | 1 |
| Cherry, SR | 1 |
| Toyokuni, T | 1 |
| Canudas, AM | 1 |
| Akerund, P | 1 |
| de Almeida, LP | 2 |
| Zala, D | 1 |
| Wei, W | 1 |
| Qian, Y | 1 |
| Puschban, Z | 2 |
| Romero, N | 1 |
| Sulzer, D | 1 |
| Rice, M | 1 |
| Tkác, I | 1 |
| Keene, CD | 1 |
| Pfeuffer, J | 1 |
| Low, WC | 1 |
| Gruetter, R | 1 |
| MacGibbon, GA | 1 |
| Hamilton, LC | 1 |
| Crocker, SF | 1 |
| Costain, WJ | 1 |
| Murphy, KM | 1 |
| Robertson, HA | 1 |
| Denovan-Wright, EM | 1 |
| Roitberg, BZ | 1 |
| Emborg, ME | 1 |
| Sramek, JG | 1 |
| Palfi, S | 1 |
| Bensadoun, JC | 1 |
| Dréano, M | 1 |
| Frank, C | 1 |
| Tebano, MT | 1 |
| Scarchilli, L | 1 |
| Quarta, D | 1 |
| Malchiodi-Albedi, F | 1 |
| Falchi, M | 1 |
| Massotti, M | 1 |
| Hurelbrink, CB | 1 |
| Armstrong, RJ | 1 |
| Chase, K | 1 |
| Aronin, N | 1 |
| Fujiyama, F | 1 |
| Stephenson, FA | 1 |
| Bolam, JP | 1 |
| Gehlert, DR | 1 |
| Schoepp, DD | 1 |
| Sontag, KH | 1 |
| Schumacher, JM | 2 |
| Riche, D | 1 |
| Madras, BK | 1 |
| Davenport, PD | 1 |
| Maziere, M | 1 |
| Elmaleh, DR | 1 |
| Brownell, GL | 1 |
| Swartz, KJ | 3 |
| Susel, Z | 1 |
| Engber, TM | 1 |
| Kuo, S | 1 |
| Markey, SP | 1 |
| Burton, S | 1 |
| Daya, S | 1 |
| Potgieter, B | 1 |
| Taylor, R | 1 |
| Martinez-Mir, MI | 1 |
| Probst, A | 1 |
| Palacios, JM | 1 |
| Hyman, BT | 1 |
| Zubrycki, EM | 1 |
| Ragozzino, ME | 1 |
| Lu, SY | 1 |
| Norman, AB | 2 |
| Shipley, MT | 2 |
| Giordano, M | 2 |
| Ford, LM | 1 |
| Zhu, SG | 1 |
| McGeer, EG | 1 |
| McGeer, PL | 1 |
| Freese, A | 1 |
| Koroshetz, WJ | 1 |
| Martin, JB | 3 |
| Ruzicka, BB | 1 |
| Bruyn, RP | 1 |
| Stoof, JC | 1 |
| Calderon, SF | 1 |
| Tew, JM | 1 |
| Sofic, E | 1 |
| Halket, J | 2 |
| Przyborowska, A | 1 |
| Riederer, P | 1 |
| Beckmann, H | 1 |
| Sandler, M | 2 |
| Jellinger, K | 1 |
| Koh, JY | 1 |
| Peters, S | 1 |
| Choi, DW | 1 |
| Connick, JH | 1 |
| Winn, P | 1 |
| Hastings, MH | 1 |
| English, M | 1 |
| Ellison, DW | 1 |
| Malloy, JR | 1 |
| Garnett, ES | 1 |
| Brown, RR | 1 |
| Marx, JL | 1 |
| Reynolds, GP | 1 |
| Pearson, SJ | 1 |
| Okuno, E | 1 |
| White, RJ | 1 |
| Whetsell, WO | 1 |
| Davies, SW | 1 |
| Roberts, PJ | 1 |
| Tamminga, CA | 1 |
| Kurlan, R | 1 |
| Shoulson, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NMDA-Receptor Blockade in Huntington's Chorea[NCT00001930] | Phase 2 | 25 participants | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for quinolinic acid and Huntington Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; Huntington Disease; Kynurenine; Mice; Mutation; P | 2010 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Tryptophan metabolites and brain disorders.
Topics: AIDS Dementia Complex; Brain Diseases; Central Nervous System Diseases; Humans; Huntington Disease; | 2003 |
Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.
Topics: Animals; Calcium; Cell Death; Disease Models, Animal; Energy Metabolism; Excitatory Amino Acids; Hum | 2007 |
Animal models of Huntington's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Genetic Vectors; Huntington Disease; Lentiviru | 2007 |
Excitotoxic neuronal death and the pathogenesis of Huntington's disease.
Topics: Animals; Biological Transport; Humans; Huntington Disease; Neurons; Neurotoxins; Quinolinic Acid; Re | 2008 |
The use of toxins to elucidate neural function and disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain; Brain Diseases; Disease Models, Animal; Humans; | 1993 |
The quinolinic acid hypothesis in Huntington's chorea.
Topics: Brain; Humans; Huntington Disease; Neurotoxins; Pyridines; Quinolinic Acid; Quinolinic Acids; Recept | 1990 |
Endogenous excitotoxic agents.
Topics: Animals; Aspartic Acid; Cell Survival; Central Nervous System; Dementia; Epilepsy; Glutamates; Gluta | 1987 |
198 other studies available for quinolinic acid and Huntington Disease
| Article | Year |
|---|---|
Mast cells and histamine are involved in the neuronal damage observed in a quinolinic acid-induced model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Female; Histamine; Huntington Disease; Mast Cells; Mice; Mice, Inbr | 2022 |
Anti-inflammatory effects of ellagic acid and vanillic acid against quinolinic acid-induced rat model of Huntington's disease by targeting IKK-NF-κB pathway.
Topics: Acetylcholinesterase; Animals; Anti-Inflammatory Agents; Antioxidants; Caspase 3; Ellagic Acid; Hunt | 2022 |
Bacillus calmette gaurine vaccine ameliorates the neurotoxicity of quinolinic acid in rats via the modulation of antioxidant, inflammatory and apoptotic markers.
Topics: Animals; Antioxidants; BCG Vaccine; Corpus Striatum; Disease Models, Animal; Huntington Disease; Neu | 2023 |
Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Humans; Huntington Disease; Mice; Neoplasm Gradin | 2020 |
In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
Topics: Animals; Anticonvulsants; Autoradiography; Corpus Striatum; Female; Huntington Disease; Hydroxydopam | 2021 |
Longitudinal Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging in Sheep (Ovis aries) With Quinolinic Acid Lesions of the Striatum: Time-Dependent Recovery of N-Acetylaspartate and Fractional Anisotropy.
Topics: Animals; Anisotropy; Corpus Striatum; Diffusion Tensor Imaging; Disease Models, Animal; Huntington D | 2020 |
Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Doublecortin Domain Proteins; Doublecortin Protein | 2020 |
Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.
Topics: Aminopyridines; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic AMP Respo | 2021 |
5,6,7 trihydroxy flavone armoured neurodegeneration caused by Quinolinic acid induced huntington's like disease in rat striatum - reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathol
Topics: Animals; Brain; Cognition; Corpus Striatum; Disease Models, Animal; Flavones; Huntington Disease; Ma | 2022 |
The Effect of Tissue Preparation and Donor Age on Striatal Graft Morphology in the Mouse.
Topics: Animals; Brain Tissue Transplantation; Cell Differentiation; Cells, Cultured; Corpus Striatum; Disea | 2018 |
Generating Excitotoxic Lesion Models of Huntington's Disease.
Topics: Animals; Atrophy; Disease Models, Animal; Humans; Huntington Disease; Interneurons; Mice; Microinjec | 2018 |
Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone-a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats.
Topics: Animals; Brain; Edaravone; Free Radical Scavengers; Huntington Disease; Lipid Peroxidation; Male; Ne | 2018 |
Longitudinal characterization of cognitive and motor deficits in an excitotoxic lesion model of striatal dysfunction in non-human primates.
Topics: Animals; Cognitive Dysfunction; Corpus Striatum; Disease Models, Animal; Huntington Disease; Longitu | 2019 |
Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
Topics: Aging; Animals; Brain; Cerebellum; Corpus Striatum; Female; Genotype; Huntington Disease; Indoleamin | 2013 |
Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.
Topics: Aging; Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Huntingti | 2012 |
Donor age dependent graft development and recovery in a rat model of Huntington's disease: histological and behavioral analysis.
Topics: Age Factors; Animals; Apomorphine; Brain Tissue Transplantation; Corpus Striatum; Disease Models, An | 2013 |
The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; H | 2013 |
Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences.
Topics: Animals; Behavior, Animal; Brain; Caspase 3; Disease Models, Animal; Drug Synergism; Electron Transp | 2013 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; | 2014 |
Improvement of mitochondrial function by paliperidone attenuates quinolinic acid-induced behavioural and neurochemical alterations in rats: implications in Huntington's disease.
Topics: Acetylcholinesterase; Animals; Biogenic Amines; Body Weight; Corpus Striatum; Huntington Disease; Is | 2014 |
Transplantation of induced pluripotent stem cells improves functional recovery in Huntington's disease rat model.
Topics: Animals; Blotting, Western; Cell Differentiation; Cells, Cultured; Corpus Striatum; Disease Models, | 2014 |
Sub-chronic copper pretreatment reduces oxidative damage in an experimental Huntington's disease model.
Topics: Animals; Apomorphine; Copper; Disease Models, Animal; gamma-Aminobutyric Acid; Huntington Disease; L | 2014 |
Improvement of mitochondrial NAD(+)/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease.
Topics: Animals; Antioxidants; Caffeine; Cell Respiration; Corpus Striatum; Disease Models, Animal; Dose-Res | 2014 |
Behavioural profile of Wistar rats with unilateral striatal lesion by quinolinic acid (animal model of Huntington disease) post-injection of apomorphine and exposure to static magnetic field.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agonis | 2015 |
Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism.
Topics: Animals; Body Weight; Cell Death; Corpus Striatum; Disease Models, Animal; Dose-Response Relationshi | 2015 |
Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats.
Topics: Adenosine; Alkaloids; Animals; Antioxidants; Benzodioxoles; Brain; Catecholamines; Curcumin; Cytokin | 2016 |
Essential fatty acid-rich diets protect against striatal oxidative damage induced by quinolinic acid in rats.
Topics: Animals; Body Weight; Cholesterol; Corpus Striatum; Disease Models, Animal; Fatty Acids, Essential; | 2017 |
The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Brain; Disease Models, Anima | 2016 |
Aberrant self-grooming as early marker of motor dysfunction in a rat model of Huntington's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Grooming; Huntingto | 2016 |
Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
Topics: Animals; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Huntington | 2017 |
Intact intracortical microstimulation (ICMS) representations of rostral and caudal forelimb areas in rats with quinolinic acid lesions of the medial or lateral caudate-putamen in an animal model of Huntington's disease.
Topics: Animals; Brain Mapping; Disease Models, Animal; Electric Stimulation; Forelimb; Huntington Disease; | 2008 |
Microanatomical evidences for potential of mesenchymal stem cells in amelioration of striatal degeneration.
Topics: Animals; Bone Marrow Transplantation; Cerebral Ventricles; Corpus Striatum; Disease Models, Animal; | 2008 |
Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats.
Topics: Animals; Cell Culture Techniques; Cell Differentiation; Cell Proliferation; Corpus Striatum; Culture | 2008 |
Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease.
Topics: Animals; bcl-2-Associated X Protein; Calcium-Binding Proteins; Eliminative Behavior, Animal; Hunting | 2008 |
Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lipid Peroxidation; Male; Meta | 2009 |
Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.
Topics: Animals; Brain; Brain Ischemia; Cells, Cultured; Dendritic Spines; Disease Models, Animal; Disease P | 2009 |
Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Survival; Cerebral Cortex; Corpus Striatum; Cyclic | 2009 |
Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease.
Topics: Anesthetics, Inhalation; Animals; Antiparkinson Agents; Apomorphine; Brain; Disease Models, Animal; | 2009 |
Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Functional Laterality; Huntingto | 2010 |
Spermine improves recognition memory deficit in a rodent model of Huntington's disease.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory | 2009 |
Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.
Topics: Adult; Aged; Animals; Brain; Brain-Derived Neurotrophic Factor; Calcineurin; Calcineurin Inhibitors; | 2009 |
NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/prooxidant model of Huntington's disease in rats: protective role of apocynin.
Topics: Acetophenones; Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lipid Peroxidat | 2010 |
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Topics: Animals; Anti-Bacterial Agents; Biomarkers; Corpus Striatum; Humans; Huntingtin Protein; Huntington | 2009 |
Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.
Topics: Animals; Body Weight; Caffeic Acids; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Disease Models, A | 2009 |
Slowed progression in models of Huntington disease by adipose stem cell transplantation.
Topics: Adipocytes; Animals; Cell Line, Tumor; Cells, Cultured; Corpus Striatum; Culture Media, Conditioned; | 2009 |
Adenoviral gene delivery of pigment epithelium-derived factor protects striatal neurons from quinolinic acid-induced excitotoxicity.
Topics: Adenoviridae; Amino Acid Sequence; Animals; Biomarkers; Choline O-Acetyltransferase; Corpus Striatum | 2010 |
Comparison of transplant efficiency between spontaneously derived and noggin-primed human embryonic stem cell neural precursors in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Carrier Proteins; Cell Differentiation; Cell Movement; Cell Survival; Disease Models, Anima | 2010 |
Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.
Topics: Animals; Antioxidants; Benzhydryl Compounds; Body Weight; Corpus Striatum; Disease Models, Animal; E | 2010 |
BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.
Topics: Animals; Astrocytes; Brain-Derived Neurotrophic Factor; Glial Fibrillary Acidic Protein; Huntington | 2010 |
Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism.
Topics: Animals; Brain; Female; Glucose; Huntington Disease; Positron-Emission Tomography; Pyridines; Quinol | 2010 |
Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats.
Topics: Analysis of Variance; Animals; Apoptosis; Body Weight; Calcium Channel Blockers; Catalase; Cytokines | 2011 |
Licofelone attenuates quinolinic acid induced Huntington like symptoms: possible behavioral, biochemical and cellular alterations.
Topics: Animals; Behavior, Animal; Biochemical Phenomena; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Dise | 2011 |
γ-Aminobutyric acid type B receptor changes in the rat striatum and substantia nigra following intrastriatal quinolinic acid lesions.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Female; Huntington Disease; Immunohist | 2011 |
Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats.
Topics: Animals; Brain; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; H | 2011 |
Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
Topics: Animals; Brain; Calcineurin; Cell Death; Disease Models, Animal; Gene Expression Regulation; Gene Pr | 2011 |
Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models.
Topics: Animals; Apoptosis; Bone Marrow Transplantation; Caspase 3; Cell Differentiation; Cell Movement; Cel | 2011 |
Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Topics: Animals; Antioxidants; Convulsants; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lip | 2012 |
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease.
Topics: Animals; Cell Differentiation; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Humans; Hun | 2012 |
Brain repair in a unilateral rat model of Huntington's disease: new insights into impairment and restoration of forelimb movement patterns.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Fetal Tissue Transplantation; Forelimb; H | 2013 |
Transplantation of GABAergic cells derived from bioreactor-expanded human neural precursor cells restores motor and cognitive behavioral deficits in a rodent model of Huntington's disease.
Topics: Animals; Behavior, Animal; Cell Transdifferentiation; Cells, Cultured; Disease Models, Animal; Femal | 2013 |
Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons.
Topics: Animals; Cell Adhesion; Cell Differentiation; Cell Lineage; Cell Survival; Cell Transplantation; Dop | 2013 |
Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin.
Topics: Animals; Behavior, Animal; Catalase; Disease Models, Animal; Huntington Disease; Male; Melatonin; Mo | 2013 |
Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Brain; Choline O-Acetyltransferase; Ciliary Neurotrophic Factor; Disease Models, Animal; DN | 2002 |
Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain after quinolinic acid lesion: comparison with the dopamine receptor imaging.
Topics: Animals; Autoradiography; Benzazepines; Brain; Carbon Radioisotopes; Cerebellum; Corpus Striatum; Hu | 2002 |
Adenosine A(2A) antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease.
Topics: Adenosine; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Extracellular Space; Glut | 2003 |
Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain.
Topics: Animals; Blotting, Western; Brain Injuries; Brain-Derived Neurotrophic Factor; Calcium-Binding Prote | 2003 |
Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administrat | 2003 |
Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: a potential novel treatment in a rat model of Huntington's disease.
Topics: Animals; Basal Ganglia; Corpus Striatum; Discrimination Learning; Disease Models, Animal; Female; Gl | 2003 |
Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
Topics: Animals; Apoptosis; Cell Division; Cell Survival; Corpus Striatum; DNA Damage; Dose-Response Relatio | 2004 |
Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Cognition; D | 2004 |
Glutamatergic regulation of long-term grafts of fetal lateral ganglionic eminence in a rat model of Huntington's disease.
Topics: Animals; Brain Injuries; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dizo | 2004 |
Quinolinic acid lesions of the caudate putamen in the rat lead to a local increase of ciliary neurotrophic factor.
Topics: Animals; Blotting, Western; Caudate Nucleus; Ciliary Neurotrophic Factor; Huntington Disease; Immuno | 2004 |
Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Drug Administration Routes; Enzyme Inhibitors; Guanidines; Huntingt | 2004 |
AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Calbindins; Choline O-Acetyltransferase; Corpus Striatum | 2004 |
Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Line; Cell Transplantation; Choline O- | 2004 |
Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Exploratory Behavior; Huntington Disease; Male; Mo | 2004 |
3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
Topics: Aged; Animals; Butyrates; Case-Control Studies; Cerebellum; Corpus Striatum; Frontal Lobe; Humans; H | 2003 |
Human neural stem cell transplants improve motor function in a rat model of Huntington's disease.
Topics: Animals; Astrocytes; Cell Differentiation; Cells, Cultured; Cerebral Cortex; Ciliary Neurotrophic Fa | 2004 |
Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
Topics: Animals; Biomarkers; Bromodeoxyuridine; Cell Death; Cell Differentiation; Cell Division; Cell Moveme | 2004 |
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2005 |
Neuroprotection by encapsulated choroid plexus in a rodent model of Huntington's disease.
Topics: Alginates; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain Tis | 2004 |
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
Topics: Aged; Analysis of Variance; Cerebellum; Cerebral Cortex; Frontal Lobe; Humans; Huntington Disease; K | 2004 |
Minocycline in phenotypic models of Huntington's disease.
Topics: Animals; Calpain; Caspases; Cell Death; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Do | 2005 |
Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
Topics: Animals; Benzamides; Brain Chemistry; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antago | 2005 |
Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Corpus Striatum; Cyclopropanes; Denerva | 2005 |
Training specificity, graft development and graft-mediated functional recovery in a rodent model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Count; Corpus Striatum; Disease Models | 2005 |
Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Count; Cells, Cultured; Corpus Striatum; Disease Models | 2005 |
Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Antineoplastic Agents; Carrier Proteins; Caspases; | 2005 |
Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity.
Topics: Adult; Aged, 80 and over; Animals; Calbindins; Choline O-Acetyltransferase; Corpus Striatum; Disease | 2005 |
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Topics: Animals; Brain Chemistry; Excitatory Amino Acid Agonists; Huntington Disease; Kainic Acid; Kynurenic | 2006 |
Noninvasive method of immortalized neural stem-like cell transplantation in an experimental model of Huntington's disease.
Topics: Animals; Cell Line, Transformed; Cell Movement; Humans; Huntington Disease; Immunohistochemistry; Im | 2006 |
Neural progenitor implantation restores metabolic deficits in the brain following striatal quinolinic acid lesion.
Topics: Analysis of Variance; Animals; Apomorphine; Autoradiography; Behavior, Animal; Cell Count; Corpus St | 2006 |
Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
Topics: Animals; Calbindin 2; Calbindins; Cell Count; Choline O-Acetyltransferase; Corpus Striatum; Cyclic A | 2006 |
Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.
Topics: Analysis of Variance; Animals; Animals, Genetically Modified; Brain; Disease Models, Animal; Fluores | 2006 |
Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Bromodeoxyuridine; Cell Co | 2006 |
Quinolinic acid modulates the activity of src family kinases in rat striatum: in vivo and in vitro studies.
Topics: Animals; Corpus Striatum; CSK Tyrosine-Protein Kinase; Dose-Response Relationship, Drug; Down-Regula | 2006 |
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Topics: Age Factors; Animals; Brain Chemistry; Chromatography, Gas; Chromatography, High Pressure Liquid; Di | 2006 |
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.
Topics: Active Transport, Cell Nucleus; Animals; Brain; Caspase 6; Caspases; Cell Nucleus; Humans; Huntingti | 2006 |
Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
Topics: Analysis of Variance; Animals; Blotting, Western; Cell Death; Cyclooxygenase 2; Disease Models, Anim | 2006 |
Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease.
Topics: Aging; Animals; Disease Models, Animal; Doublecortin Domain Proteins; Huntington Disease; Immunohist | 2006 |
Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Behavior, Animal; Behavioral Sympt | 2007 |
Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains.
Topics: Animals; Chimera; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Re | 2006 |
Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.
Topics: Animals; Cell Survival; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models | 2007 |
Proteasome activator enhances survival of Huntington's disease neuronal model cells.
Topics: Cell Survival; Cells, Cultured; Corpus Striatum; Fibroblasts; Humans; Huntingtin Protein; Huntington | 2007 |
Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions.
Topics: Animals; Apomorphine; Cell Differentiation; Cell Line; Dopamine Agonists; Embryonic Stem Cells; Hunt | 2007 |
Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease.
Topics: Animals; Basal Ganglia; Calcium; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Hu | 2007 |
Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Communication; Cell Survival; Cerebral Cortex; Corp | 2008 |
AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dependovirus; Gene Expression; Genetic | 2008 |
Transplants of encapsulated rat choroid plexus cells exert neuroprotection in a rodent model of Huntington's disease.
Topics: Alginates; Animals; Capsules; Choroid Plexus; Corpus Striatum; Epithelial Cells; Glucuronic Acid; He | 2008 |
Differential vulnerability of central neurons of the rat to quinolinic acid.
Topics: Animals; Brain; Corpus Striatum; Diencephalon; Epilepsy, Temporal Lobe; Hippocampus; Huntington Dise | 1983 |
GABA and GABAA receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease.
Topics: Animals; Autoradiography; Disease Models, Animal; Flunitrazepam; Gene Expression; Huntington Disease | 1995 |
Transcription of the Huntington disease gene during the quinolinic acid excitotoxic cascade.
Topics: Animals; Blotting, Northern; Gene Expression; Huntington Disease; Male; Nerve Degeneration; Quinolin | 1995 |
Effects of striatal excitotoxicity on huntingtin-like immunoreactivity.
Topics: Animals; Antibodies; Cell Death; Corpus Striatum; Excitatory Amino Acids; Gene Expression; Huntingti | 1995 |
Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Corpus Striatum; Disease Models, Animal; DNA; DN | 1995 |
Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Huntington Disease; Macaca mulat | 1995 |
Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.
Topics: Adult; Aged; Aged, 80 and over; Animals; Base Sequence; Calbindin 1; Calbindins; Cells, Cultured; Hu | 1995 |
Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Functional Laterali | 1995 |
Behavioral and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease in rats.
Topics: Animals; Behavior, Animal; Body Weight; Disease Models, Animal; Electric Stimulation; Electroencepha | 1994 |
Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
Topics: Animals; Antibodies; Cell Survival; Choline O-Acetyltransferase; Corpus Striatum; Efferent Pathways; | 1994 |
Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Disease Models, Animal; Enzyme Induction; Fem | 1994 |
Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Biopterins; HIV Infections; Humans; Hunti | 1994 |
CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease.
Topics: Adenosine; Amphetamine; Animals; Disease Models, Animal; Huntington Disease; Male; Motor Activity; P | 1994 |
Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.
Topics: Animals; Antibodies, Monoclonal; Corpus Striatum; Huntington Disease; Male; Nerve Degeneration; Nerv | 1994 |
The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat.
Topics: Adult; Aged; Animals; Autoradiography; Basal Ganglia; Female; Flunitrazepam; Humans; Huntington Dise | 1993 |
Huntington's disease and low tryptophan diet.
Topics: Brain; Female; Humans; Huntington Disease; Models, Biological; Nerve Degeneration; Quinolinic Acid; | 1993 |
Visual evoked potentials in the rat quinolinic acid model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Evoked Potentials, Visual; Huntington Disease; Inj | 1993 |
Remote microglial activation in the quinolinic acid model of Huntington's disease.
Topics: Animals; Corpus Striatum; Globus Pallidus; Huntington Disease; Male; Microglia; Neural Pathways; Qui | 1993 |
Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum.
Topics: Animals; Corpus Callosum; Corpus Striatum; Fibroblasts; Huntington Disease; Male; Nerve Growth Facto | 1993 |
Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.
Topics: Animals; Brain; Caudate Nucleus; Disease Models, Animal; Histocytochemistry; Huntington Disease; Imm | 1993 |
Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington's disease.
Topics: Animals; Cognition; Corpus Striatum; Habituation, Psychophysiologic; Huntington Disease; Locomotion; | 1996 |
Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Death; Ciliary Neurotrophic Factor; Corpus Striatum | 1996 |
DARPP-32-rich zones in grafts of lateral ganglionic eminence govern the extent of functional recovery in skilled paw reaching in an animal model of Huntington's disease.
Topics: Acetylcholinesterase; Animals; Brain Tissue Transplantation; Cyclic N-Oxides; Dopamine and cAMP-Regu | 1996 |
Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
Topics: Animals; Brain; Cell Line; Ciliary Neurotrophic Factor; Corpus Striatum; Cricetinae; Disease Models, | 1997 |
Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain Chemistry; Choline O-Acetyltransferase; Female; Glial Cell Line-Der | 1997 |
Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Excitatory Amino Acid Agonists; | 1997 |
Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment.
Topics: Animals; Autoradiography; Benzazepines; Binding, Competitive; Cholinergic Agents; Corpus Striatum; D | 1998 |
Electrolytic lesion of globus pallidus ameliorates the behavioral and neurodegenerative effects of quinolinic acid lesion of the striatum: a potential novel treatment in a rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Electrolysis; Globus Pallidus; Huntington Disease; | 1998 |
Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Topics: Alanine; Animals; Anticonvulsants; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism | 1998 |
Effects of severity of host striatal damage on the morphological development of intrastriatal transplants in a rodent model of Huntington's disease: implications for timing of surgical intervention.
Topics: Acetylcholinesterase; Animals; Atrophy; Cell Count; Cell Survival; Cell Transplantation; Corpus Stri | 1998 |
Striatal lesions produce distinctive impairments in reaction time performance in two different operant chambers.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Excitatory Amino Aci | 1998 |
Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
Topics: Animals; Cerebral Ventricles; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV | 1998 |
Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Behavior, Animal; Benzofurans; Choline O-Acetylt | 1998 |
Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain-Derived Neurotrophic Factor | 1998 |
Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain Tissue Transp | 1999 |
Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
Topics: Activins; Animals; Calbindin 2; Choline O-Acetyltransferase; Corpus Striatum; gamma-Aminobutyric Aci | 1999 |
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
Topics: Animals; Biomarkers; Brain; Cell Count; Cell Survival; Corpus Striatum; Exons; Humans; Huntington Di | 1999 |
The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Electroencephalography; Frontal Lobe; Huntington D | 1999 |
Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia.
Topics: Animals; Basal Ganglia; Corpus Striatum; Cytoskeleton; Disease Models, Animal; DNA Damage; Efferent | 1999 |
The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Topics: Animals; Calbindin 2; Calbindins; Cell Count; Choline O-Acetyltransferase; Cholinergic Fibers; Corpu | 1999 |
Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes.
Topics: Animals; Autoradiography; Corpus Striatum; Disease Models, Animal; Huntington Disease; Immunohistoch | 1999 |
Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage.
Topics: Animals; Biodegradation, Environmental; Capsules; Choline O-Acetyltransferase; Corpus Striatum; Dopa | 2000 |
Imaging the rat brain on a 1.5 T clinical MR-scanner.
Topics: Animals; Artifacts; Blood-Brain Barrier; Brain; Brain Tissue Transplantation; Female; Huntington Dis | 2000 |
Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease.
Topics: Acetylcholinesterase; Animals; Brain Tissue Transplantation; Cell Count; Cell Differentiation; Cell | 2000 |
Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Implants, Experimental; Male; | 2000 |
Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.
Topics: Animals; Calbindins; Cell Count; Choline O-Acetyltransferase; Corpus Striatum; Disease Models, Anima | 2000 |
Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide.
Topics: Animals; Antineoplastic Agents; Autoradiography; Benzamides; Biocompatible Materials; Corpus Striatu | 2000 |
Metabolic changes after injection of quinolinic acid or 6-hydroxydopamine in the rat striatum: a time-course study using cytochrome oxidase and glycogene phosphorylase a histochemistry.
Topics: Animals; Autoradiography; Benzazepines; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamin | 2000 |
Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.
Topics: Animals; Autoradiography; Benzazepines; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine A | 2000 |
Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area.
Topics: 3T3 Cells; Animals; Axonal Transport; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Colchicine | 2001 |
Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Death; Cell Line; Cell Transplantation; Corpus Stri | 2000 |
Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; beta-Galactosidase; Ciliary Neurotrophic Factor; Cytomegalovirus; Disease Models, Animal; F | 2001 |
Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.
Topics: Animals; Antimanic Agents; Benzazepines; Cell Death; Cyclin D1; Disease Models, Animal; Dopamine Ant | 2001 |
Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.
Topics: Aging; Animals; Ascorbic Acid; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Respons | 2001 |
Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy.
Topics: Amino Acids; Animals; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Energy M | 2001 |
Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
Topics: Animals; Anti-Dyskinesia Agents; Central Nervous System Stimulants; Corpus Callosum; Corpus Striatum | 2002 |
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
Topics: Animals; Brain Mapping; Caudate Nucleus; Cebus; Disease Models, Animal; Frontal Lobe; Humans; Huntin | 2002 |
Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome.
Topics: Acetylcholine; Animals; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Genetic Vectors; Hu | 2001 |
Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.
Topics: Animals; Behavior, Animal; Calcium; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dose-R | 2002 |
Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease.
Topics: Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Enkephalins; Globus Pallidus; Gluta | 2002 |
Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS.
Topics: Animals; Brain Tissue Transplantation; Cell Differentiation; Cell Movement; Disease Models, Animal; | 2002 |
Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; He | 2002 |
Synaptic localization of GABA(A) receptor subunits in the substantia nigra of the rat: effects of quinolinic acid lesions of the striatum.
Topics: Animals; Dendrites; Female; Functional Laterality; gamma-Aminobutyric Acid; Huntington Disease; Immu | 2002 |
Striatal quinolinic acid lesions increase [3H]WIN 35,428 binding to the dopamine transporter.
Topics: Animals; Autoradiography; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine Plasma Membrane Trans | 1992 |
Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Evoked Potentials, Somatosensory; Huntington Disea | 1992 |
A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Carbon Radioisotopes; Caudate Nucleus; Cocaine; | 1992 |
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Atrophy; Biogenic Amines; Cerebra | 1991 |
Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease.
Topics: Animals; Choline O-Acetyltransferase; Convulsants; Corpus Striatum; Disease Models, Animal; Glutamat | 1991 |
Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease.
Topics: Adult; Brain Chemistry; Convulsants; Female; Humans; Huntington Disease; Male; Middle Aged; Organ Sp | 1991 |
Melatonin modulates apomorphine-induced rotational behaviour.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Hun | 1991 |
A lot of "excitement' about neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Alzheimer Disease; Animals; Dizocilpine Maleate | 1991 |
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease.
Topics: Adenosine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Female; Guinea Pigs; Hu | 1991 |
Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids.
Topics: Animals; Cell Line; Corpus Striatum; Disease Models, Animal; Fibroblasts; Genetic Engineering; Hunti | 1991 |
NADPH-diaphorase-containing neurons and cytochrome oxidase activity following striatal quinolinic acid lesions and fetal striatal transplants.
Topics: Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Electron Transport C | 1990 |
Neural grafts and pharmacological intervention in a model of Huntington's disease.
Topics: Acetylcholinesterase; Amphetamine; Animals; Brain Tissue Transplantation; Catalepsy; Cerebral Cortex | 1990 |
gamma-Glutamyltransferase activity is unchanged in acutely quinolinate-lesioned rat neostriatum but is elevated in Huntington's disease caudate.
Topics: Animals; Caudate Nucleus; Corpus Striatum; gamma-Glutamyltransferase; Humans; Huntington Disease; Ma | 1990 |
Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures.
Topics: 2-Amino-5-phosphonovalerate; Animals; Calcium; Cells, Cultured; Corpus Striatum; Glutamates; Glutami | 1990 |
Elevation of Met-enkephalin-like immunoreactivity in the rat striatum and globus pallidus following the focal injection of excitotoxins.
Topics: Animals; Corpus Striatum; Enkephalin, Methionine; Globus Pallidus; Huntington Disease; Injections; K | 1990 |
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Topics: 2-Amino-5-phosphonovalerate; Allopurinol; Amino Acids; Animals; Antioxidants; Baclofen; Corpus Stria | 1988 |
The quinolinic acid model of Huntington's disease: locomotor abnormalities.
Topics: Animals; Behavior, Animal; Brain; Contraceptives, Oral, Combined; Huntington Disease; Locomotion; Ma | 1989 |
Brain quinolinic acid in Alzheimer's dementia.
Topics: Adult; Aged; Alzheimer Disease; Brain; Cerebellum; Female; Frontal Lobe; Humans; Huntington Disease; | 1989 |
Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity.
Topics: Animals; Aspartic Acid; Glutamates; Glutamic Acid; Humans; Huntington Disease; Kainic Acid; Mice; N- | 1986 |
Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease.
Topics: Amino Acids; Animals; Brain; Decerebrate State; Humans; Huntington Disease; Neurotransmitter Agents; | 1987 |
Normal excretion of quinolinic acid in Huntington's disease.
Topics: Adolescent; Adult; Creatinine; Female; Humans; Huntington Disease; Male; Middle Aged; Pyridines; Qui | 1985 |
Animals yield clues to Huntington's disease.
Topics: Animals; Brain; Disease Models, Animal; Humans; Huntington Disease; Neurons; Quinolinic Acid; Quinol | 1987 |
Brain quinolinic acid in Huntington's disease.
Topics: Brain; Frontal Lobe; Gas Chromatography-Mass Spectrometry; Humans; Huntington Disease; Putamen; Pyri | 1988 |
3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; Brain; Brain Mapping; Caudate Nucleus; Dioxygenases; Humans; | 1988 |
Model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Huntington Disease; Quinolinic Acid; Quinolinic Acids | 1988 |
Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia.
Topics: Adolescent; Adult; Female; Humans; Huntington Disease; Male; Middle Aged; Pyridines; Quinolinic Acid | 1988 |